Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.

A liquid crystal composition without requiring an alignment film or alignment treatment on a substrate. The problem is solved by a low molecular weight polar compound capable of homogeneously aligning a liquid crystal medium relative to the substrate, for example, a low molecular weight polar compound represented by formula (1):
M-P(1) In formula (1), M is a nonpolar group having 1 or more carbons, and P is a polar group.

One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

The invention provides compounds for use in inhibiting a microbial alternative oxidase (AOX) and/or cytochrome bc.sub.1 complex. The invention extends to the use of such inhibitors in agrochemicals and in pharmaceuticals, for treating microbial infections, including fungal infections.

The invention provides compounds for use in inhibiting a microbial alternative oxidase (AOX) and/or cytochrome bc.sub.1 complex. The invention extends to the use of such inhibitors in agrochemicals and in pharmaceuticals, for treating microbial infections, including fungal infections.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.

A liquid crystal display device having a liquid crystal composition, requiring neither an alignment film nor alignment treatment on a substrate. The problem is solved by a low molecular weight polar compound for homogeneously aligning a liquid crystal medium relative to the substrate, for example, the low molecular weight polar compound represented by formula (1).
Formula 95
M-P(1) In formula (1), M is a nonpolar group having 1 or more carbons, and P is a polar group.

A liquid crystal display device having a liquid crystal composition, requiring neither an alignment film nor alignment treatment on a substrate. The problem is solved by a low molecular weight polar compound for homogeneously aligning a liquid crystal medium relative to the substrate, for example, the low molecular weight polar compound represented by formula (1).
Formula 95
M-P(1) In formula (1), M is a nonpolar group having 1 or more carbons, and P is a polar group.